Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
590
datasets available to search
ShareScore release 0.9.0
Dataset results
590 results for “Irritable bowel syndrome”
(FODMAP) Diet on Improving Symptoms of Patients With Irritable Bowel Syndrome
ClinicalTrials.gov study NCT07299305. IPD Sharing: NO. Countries: 1. Publications: 0.
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
ClinicalTrials.gov study NCT00945334. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
ClinicalTrials.gov study NCT01553591. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome
ClinicalTrials.gov study NCT03457324. IPD Sharing: YES. Countries: 1. Publications: 2.
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
ClinicalTrials.gov study NCT00460811. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
ClinicalTrials.gov study NCT01543178. IPD Sharing: Not stated. Countries: 3. Publications: 6.
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
ClinicalTrials.gov study NCT01130272. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
ClinicalTrials.gov study NCT00724126. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
ClinicalTrials.gov study NCT04026113. IPD Sharing: YES. Countries: 14. Publications: 1.
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?
ClinicalTrials.gov study NCT00911612. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
ClinicalTrials.gov study NCT02328547. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)
ClinicalTrials.gov study NCT01253408. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)
ClinicalTrials.gov study NCT00616200. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
ClinicalTrials.gov study NCT02559206. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Acceptability and Efficacy of the Zemedy App for Irritable Bowel Syndrome
ClinicalTrials.gov study NCT04170686. IPD Sharing: NO. Countries: 1. Publications: 1.
The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
ClinicalTrials.gov study NCT02431533. IPD Sharing: Not stated. Countries: 1. Publications: 5.
An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
ClinicalTrials.gov study NCT00401258. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
ClinicalTrials.gov study NCT02493452. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
ClinicalTrials.gov study NCT01327300. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Data from: Artificial intelligence model for analyzing colonic endoscopy images to detect changes associated with irritable bowel syndrome
<p><strong><span>Background/Aims</span></strong></p> <p><span>IBS is not considered to be an organic disease and usually shows no abnormality on lower gastrointestinal endoscopy, although biofilm formation, dysbiosis, and histological microinflammation have recently been reported in patients with IBS. In this study, we investigated whether an artificial intelligence (AI) colorectal image model can identify minute endoscopic changes, which cannot typically be detected by human investigators, that are associated with IBS.</span></p> <p><span>Study subjects were identified based on electronic medical records and categorized as IBS (Group I; n=11), IBS with predominant constipation (IBS-C; Group C; n=12), and IBS with predominant diarrhea (IBS-D; Group D; n=12). The study subjects had no other diseases. Colonoscopy images from IBS patients and from asymptomatic healthy subjects (Group N; n=88) were obtained. Google Cloud Platform AutoML Vision (single-label classification) was used to construct AI image models to calculate sensitivity, specificity, predictive value, and AUC. A total of 2479, 382, 538, and 484 images were randomly selected for Groups N, I, C and D, respectively. </span></p> <p><strong><span>Results</span></strong></p> <p><span>The AUC of the model discriminating between Group N and I was 0.95. Sensitivity, specificity, positive predictive value, and negative predictive value of Group I detection were 30.8%, 97.6%, 66.7%, and 90.2%, respectively. The overall AUC of the model discriminating between Groups N, C, and D was 0.83; sensitivity, specificity, and positive predictive value of Group N were 87.5%, 46.2%, and 79.9%, respectively.</span></p> <p><strong><span>Conclusions</span></strong></p> <p><span>Using the image AI model, colonoscopy images of IBS could be discriminated from healthy subjects at AUC 0.95. Prospective studies are needed to further validate whether this externally validated model has similar diagnostic capabilities at other facilities and whether it can be used to determine treatment efficacy.</span></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.